There is published evidence of EGFR activity in promoting tumor angiogenesis [59, 60], which is why we included the inhibitors cetuximab and erlotinib hydrochloride in our screen of angiostatics, but EGFR also has many other activities involved in cancer progression including tumor cell growth, proliferation, and survival [61]. This evidence concerns the gene EGFR and neoplasm.